The breakthrough is the result of Dr David Langton’s (a licenced surgeon who directs ExplantLab and holds a PhD in immunological responses to medical implants) 14 years of study at ExplantLab.
A biotech company in Newcastle’s city centre employs researchers who believe they have uncovered a finding that might revolutionise orthopaedic surgery.
Helix-based ExplantLab found a genetic connection that may explain why some patients suffer discomfort and early joint replacement failure, such as with new hips. In their lifetime, 10% of people in the UK will have a joint replaced surgically, and according to ExplantLab, a considerable portion of these patients experience early failure, which can necessitate costly and sometimes deadly repeat surgery.
A large portion of joint failures is caused by unfavourable immune reactions, according to Dr David Langton, a trained surgeon and CEO of the biotech company. This occurs when tiny particles from the joint implant are released into the blood through wear and tear and trigger an immune response in the body.
In essence, the implant is attacked by the immune system in a manner akin to how a patient rejects an organ transplant. The rate at which this “sensitisation” occurs varies and is unexpected, although it appears to be influenced by the kind of material, how much wear debris is produced, and other patient-specific variables.
Dr Langton and his team investigated the composition of failed replacement joints in particular. About 70% of implants worldwide utilise a substance called cobalt chrome (CoCr). Tiny particles that are released into the blood of patients may cause a reaction.
ExplantLab discovered that a sizable percentage of patients had a genotype—the genetic composition of a single cell—that increases their likelihood of being sensitive to CoCr. The discovery was reported in Nature Communications Medicine, a prestigious magazine for scientific research.
An algorithm dubbed Orthotype, which analyses a patient’s risk has now been developed by the Newcastle team in collaboration with professionals and patients at Newcastle University, University Hospital of North Tees, Hospital for Special Surgery in New York, and Royal Perth Hospital in Australia. The technology may be used before or after joint replacement surgery to help choose the optimal implant for a patient or to support a clinical diagnosis. It has been registered for usage in the UK.
Orthotype, according to Dr Langton, aids in the identification of patients and the understanding of the risks prior to surgery, representing a significant improvement in orthopaedic care for patients as well as a step-change for orthopaedic surgeons. Orthotype may have significant financial implications for international healthcare systems by preventing the need for repeat surgery.
The discovery is merely ExplantLab’s most recent triumph; the company has previously produced award-winning research on Covid. With the assistance of Newcastle University, Northumbria Healthcare, Newcastle Hospitals Trust, and the University of Oslo, the company discovered a gene that provides defence against virus-related severe problems.
Dr Langton continued by pointing out an intriguing correlation between the frequency of this particular gene and population latitude, which may help explain why the disease’s effects vary around the world.
Dr Langton concluded by saying, We are extremely grateful to the patients who donated their time, as well as to our academic partners at Newcastle University, University Hospital of North Tees, Hospital for Special Surgery in New York, and the Centre for Implant Retrieval Analysis in Perth, Australia. Tees, Perth, HSS NYC) and Arthroplasty for Arthritis who diligently and skillfully participated in this study.
